Identifying mutations in patient-derived melanoma DCC lines

To identify mutations that cause resistance, we analyzed two patient-derived cell lines: Mel-DCC-11 (the parental line, sensitive to the BRAF inhibitor) and Mel-DCC-11-R (resistant to the BRAF inhibitor). We employed targeted-panel sequencing to examine the coding sequences of 410 cancer-associated target genes.

Type: Cancer Genomics
Archiver: European Genome-Phenome Archive (EGA)

1 Dataset 1 Publication

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD50000001745	Targeted panel sequencing was conducted on patient-derived cell lines: Mel-DCC-11 (the parental line, sensitive to the BRAF inhibitor) and Mel-DCC-11-R (resistant to the BRAF inhibitor). The parental cell line was generated from disseminated cancer cells (DCCs) obtained from a lymph node sample of a melanoma patient. The resistant cell line was generated from the parental one through exposure to Vemurafenib. Normal peripheral blood lymphocytes from the same patient served as the control for comparison. Sequencing on NovaSeq6000. Fastq files.	Illumina NovaSeq 6000	3

Publications	Citations
Micrometastasis-derived models enable drug testing for early-stage, high-risk melanoma patients. Weidele K, Werno C, Treitschke S, Botteron C, Hoffmann M, Scheitler S, Wöhrl L, Czyz Z, Feliciello G, Weber F, Ravikumar Varadarajan A, Warfsmann J, Materna-Reichelt S, Katzer M, Schreieder L, Mohammadi P, Hosseini H, Honarnejad K, Haferkamp S, Werner-Klein M, Klein CA. EMBO Mol Med 18: 2026 297-324	0